167 related articles for article (PubMed ID: 37215848)
1.
Li L; Shen X; Liang Y; Li B; Si Y; Ma R
Heliyon; 2023 May; 9(5):e15980. PubMed ID: 37215848
[TBL] [Abstract][Full Text] [Related]
2. Serum cross-linked N-telopeptide of type I collagen as a potential diagnostic marker for bone metastasis in lung cancer: An updated meta-analysis.
Wang H; Hong M; Ding L; Song B
Thorac Cancer; 2023 Mar; 14(9):787-793. PubMed ID: 36717764
[TBL] [Abstract][Full Text] [Related]
3. Serum cross-linked N-telopeptide of type I collagen for the diagnosis of bone metastases from solid tumours in the Chinese population: Meta-analysis.
Zhang Y; Yi M; Cao J; Hou C; Zhou Y; Zhong Y
J Int Med Res; 2016 Apr; 44(2):192-200. PubMed ID: 26857861
[TBL] [Abstract][Full Text] [Related]
4. Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis.
Liu B; Zhao Y; Yuan J; Zeng L; Sun R; Meng X; Yang S
PLoS One; 2017; 12(11):e0187860. PubMed ID: 29182642
[TBL] [Abstract][Full Text] [Related]
5. MiR-486 as an effective biomarker in cancer diagnosis and prognosis: a systematic review and meta-analysis.
Jiang M; Li X; Quan X; Yang X; Zheng C; Hao X; Qu R; Zhou B
Oncotarget; 2018 Mar; 9(17):13948-13958. PubMed ID: 29568407
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic value of microRNA-486 in patients with lung cancer: A systematic review and meta-analysis.
Shen X; Li L; Zhang L; Liu W; Wu Y; Ma R
Int J Biol Markers; 2022 Dec; 37(4):377-385. PubMed ID: 35902998
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer.
Tamiya M; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Yasue T; Matsuura Y; Hirashima T; Kawase I
Med Oncol; 2012 Mar; 29(1):215-8. PubMed ID: 21258879
[TBL] [Abstract][Full Text] [Related]
8. Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases.
Shizuku M; Shibata M; Okumura M; Takeuchi D; Kikumori T; Mizuno Y
Breast Cancer; 2020 Nov; 27(6):1065-1071. PubMed ID: 32415556
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis.
Li F; Huang Q; Gong Z; Wang H; Chen J
Onco Targets Ther; 2019; 12():4351-4357. PubMed ID: 31213850
[No Abstract] [Full Text] [Related]
10. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
[TBL] [Abstract][Full Text] [Related]
11. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
[TBL] [Abstract][Full Text] [Related]
12. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis.
Ali SM; Demers LM; Leitzel K; Harvey HA; Clemens D; Mallinak N; Engle L; Chinchilli V; Costa L; Brady C; Seaman J; Lipton A
Ann Oncol; 2004 Mar; 15(3):455-9. PubMed ID: 14998848
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.
Tamiya M; Kobayashi M; Morimura O; Yasue T; Nakasuji T; Satomu M; Kohei O; Takayuki S; Morishita N; Suzuki H; Sasada S; Okamoto N; Hirashima T; Kawase I
Clin Lung Cancer; 2013 Jan; 14(1):50-4. PubMed ID: 22609050
[TBL] [Abstract][Full Text] [Related]
14. Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Yanada S; Hatano T; Igarashi H; Kishimoto K; Nakada J; Yoshihiro A; Harada J
Metabolism; 2002 Jul; 51(7):814-8. PubMed ID: 12077723
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic and prognostic value of miR-92a in gastric cancer: A systematic review and meta-analysis.
Guo H; Wang Y; Wang Z; Wang Z; Xue S
Open Med (Wars); 2021; 16(1):1386-1394. PubMed ID: 34611549
[TBL] [Abstract][Full Text] [Related]
17. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
18. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.
Huang J; Gu T; Ying J
Int J Clin Oncol; 2017 Dec; 22(6):1015-1025. PubMed ID: 28677013
[TBL] [Abstract][Full Text] [Related]
20. Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis.
Washam CL; Byrum SD; Leitzel K; Ali SM; Tackett AJ; Gaddy D; Sundermann SE; Lipton A; Suva LJ
Cancer Epidemiol Biomarkers Prev; 2013 May; 22(5):972-83. PubMed ID: 23462923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
